Start
Features
Free trial / FAQ

Researchers
Physicians
Pharmacists
Ecotrophologists
Product Managers
in Health Industries

Loading…

Medical Research Finder

Legal Notice
Privacy
Terms of Use

meRfi® Microbiome - The Digital Gut Microbiome Reference (incl. AI Chat)
Prebiotics, Probiotics, FMT / Manipulators of the Intestinal Microbiota

AuthorsReferences (Sources)

meRfi® AI Chat

Tyrosine kinase inhibitors (TKIs) & Chronic myeloid leukemia / Chronic myelogenous leukemia (CML)

Welcome to meRfi Microbiome!

Please register to continue your trial period!

meRfi Microbiome provides you with up-to-date, evidence-based insights on the gut microbiota and related health topics.

Access our ever-expanding digital library and get personalized answers through our interactive AI chat platform.

Start your free trial and transform your understanding of the gut microbiota today!

(Login)

Navigation

Tyrosine kinase inhibitors have changed the natural history of chronic myeloid leukemia such that patients with adequate access to these agents, who are appropriately treated and respond well to this treatment, can expect to live a near-normal life expectancy.
Cortes et al. 2021 The Lancet 398: 1914-1926

see also:
Asciminib + Dasatinib & Chronic myeloid leukemia / Chronic myelogenous leukemia (CML)
Asciminib + Imatinib & Chronic myeloid leukemia / Chronic myelogenous leukemia (CML)
[Dasatinib & Chronic myeloid leukemia / Chronic myelogenous leukemia (CML) (Ph+ CML)](brain://d83oo_W_y0uM02Na3VnY_w/DasatinibChronicMyelo…

References (Sources)

Chronic myeloid leukaemia
Cortes et al. 2021 The Lancet 398: 1914-1926
Review

AI Chat

7/1/2026

Chat with our artificial intelligence:

Start chat!

Tyrosine kinase inhibitors (TKIs) & Chronic myeloid leukemia / Chronic myelogenous leukemia (CML)

Welcome to meRfi Microbiome!

Navigation

Contents

References (Sources)

AI Chat